Lesniak MS - Search Results

1

A Comparative Study of Replication-Incompetent and -Competent Adenoviral Therapy-Mediated Immune Response in a Murine Glioma Model.

Kim JW, Miska J, Young JS, Rashidi A, Kane JR, Panek WK, Kanojia D, Han Y, Balyasnikova IV, Lesniak MS. Kim JW, et al. Among authors: lesniak ms. Mol Ther Oncolytics. 2017 May 6;5:97-104. doi: 10.1016/j.omto.2017.05.001. eCollection 2017 Jun 16. Mol Ther Oncolytics. 2017. PMID: 28573184 Free PMC article.

2

Cross-priming of T cells to intracranial tumor antigens elicits an immune response that fails in the effector phase but can be augmented with local immunotherapy.

Velicu S, Han Y, Ulasov I, Brown IE, El Andaloussi A, Gajewski TF, Lesniak MS. Velicu S, et al. Among authors: lesniak ms. J Neuroimmunol. 2006 May;174(1-2):74-81. doi: 10.1016/j.jneuroim.2006.01.016. Epub 2006 Feb 28. J Neuroimmunol. 2006. PMID: 16504307

3

Oncolytic adenoviral therapy for glioblastoma multiforme.

Sonabend AM, Ulasov IV, Han Y, Lesniak MS. Sonabend AM, et al. Among authors: lesniak ms. Neurosurg Focus. 2006 Apr 15;20(4):E19. Neurosurg Focus. 2006. PMID: 16709024 Review.

4

CD46 represents a target for adenoviral gene therapy of malignant glioma.

Ulasov IV, Tyler MA, Zheng S, Han Y, Lesniak MS. Ulasov IV, et al. Among authors: lesniak ms. Hum Gene Ther. 2006 May;17(5):556-64. doi: 10.1089/hum.2006.17.556. Hum Gene Ther. 2006. PMID: 16716112

5

Stimulation of TLR9 with CpG ODN enhances apoptosis of glioma and prolongs the survival of mice with experimental brain tumors.

El Andaloussi A, Sonabend AM, Han Y, Lesniak MS. El Andaloussi A, et al. Among authors: lesniak ms. Glia. 2006 Nov 1;54(6):526-35. doi: 10.1002/glia.20401. Glia. 2006. PMID: 16906541

6

Prolongation of survival following depletion of CD4+CD25+ regulatory T cells in mice with experimental brain tumors.

El Andaloussi A, Han Y, Lesniak MS. El Andaloussi A, et al. Among authors: lesniak ms. J Neurosurg. 2006 Sep;105(3):430-7. doi: 10.3171/jns.2006.105.3.430. J Neurosurg. 2006. PMID: 16961139

7

Enhanced transduction of malignant glioma with a double targeted Ad5/3-RGD fiber-modified adenovirus.

Tyler MA, Ulasov IV, Borovjagin A, Sonabend AM, Khramtsov A, Han Y, Dent P, Fisher PB, Curiel DT, Lesniak MS. Tyler MA, et al. Among authors: lesniak ms. Mol Cancer Ther. 2006 Sep;5(9):2408-16. doi: 10.1158/1535-7163.MCT-06-0187. Mol Cancer Ther. 2006. PMID: 16985075

8

Novel recombinant adenoviral vector that targets the interleukin-13 receptor alpha2 chain permits effective gene transfer to malignant glioma.

Ulasov IV, Tyler MA, Han Y, Glasgow JN, Lesniak MS. Ulasov IV, et al. Among authors: lesniak ms. Hum Gene Ther. 2007 Feb;18(2):118-29. doi: 10.1089/hum.2006.146. Hum Gene Ther. 2007. PMID: 17328684

9

Fiber-knob modifications enhance adenoviral tropism and gene transfer in malignant glioma.

Zheng S, Ulasov IV, Han Y, Tyler MA, Zhu ZB, Lesniak MS. Zheng S, et al. Among authors: lesniak ms. J Gene Med. 2007 Mar;9(3):151-60. doi: 10.1002/jgm.1008. J Gene Med. 2007. PMID: 17351980

10

Survivin-driven and fiber-modified oncolytic adenovirus exhibits potent antitumor activity in established intracranial glioma.

Ulasov IV, Zhu ZB, Tyler MA, Han Y, Rivera AA, Khramtsov A, Curiel DT, Lesniak MS. Ulasov IV, et al. Among authors: lesniak ms. Hum Gene Ther. 2007 Jul;18(7):589-602. doi: 10.1089/hum.2007.002. Hum Gene Ther. 2007. PMID: 17630837

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

278 results

Search Page

Filters